ARTICLES BY THIS AUTHOR
- 3/23/2021
Uber expands prescription delivery with ScriptDrop
Uber will become the default courier for select pharmacies using ScriptDrop, depending on location and driver availability. - 3/23/2021
FDA approves Glenmark’s generic Thorazine
Thorazine had a market value of roughly $108.6 million for the 12 months ended January 2021, according to IQVIA. - 3/23/2021
NCPA releases reports reflecting on COVID-19, advocacy efforts in 2020
With two new reports, the National Community Pharmacists Association is reflecting on its extensive efforts to help independent pharmacists amid the pandemic, as well as its advocacy efforts on behalf of independent community pharmacists. - 3/23/2021
Alembic issues voluntary nationwide recall of 20-mg telmisartan
The product is being recalled due to a market complaint received, stating that one bottle labeled as 30-count telmisartan tablets 20 mg incorrectly contained 30 tablets of 40-mg telmisartan tablets. - 3/22/2021
Glenmark obtains FDA OK for generic Cardizem
Cardizem had a market value of approximately $56.7 million for the 12 months ended January 2021, according to IQVIA. - 3/22/2021
Merck creates Organon to spin off women’s health, biosimilars portfolio
Organon, a proposed spinoff of Merck's women's health, biosimilars and established brands businesses, intends to appoint a majority-female board of directors. - 3/22/2021
Zealand Pharma obtains FDA green light for Zegalogue
Zealand Pharma's Zegalogue injection is a diabetes treatment for children and adults that addresses sudden and severe hypoglycemia. - 3/22/2021
Biogen sues Teva over generic Vumerity
Biogen and Alkermes claim that Teva’s generic infringes three patents that protect Vumerity, which Alkermes licenses exclusively to Biogen. - 3/22/2021
Study finds Medicare Part D plans adding more generic drugs onto non-preferred drug tier
A study from Avalere, funded by the Association for Accessible Medicines, found that in 2021, Medicare Part D plans placed generic prescription drugs on generic tiers 45% of the time, a decrease from 64% in 2016. - 3/21/2021
Aveo intros oral renal cell carcinoma treatment Fotivda
The medication is an oral, next generation vascular endothelial growth factor tyrosine kinase inhibitor.